Brainstorm Current Deferred Revenue from 2010 to 2026

BCLI Stock  USD 0.57  0.01  1.72%   
Brainstorm Cell's Current Deferred Revenue is decreasing with slightly volatile movements from year to year. Current Deferred Revenue is estimated to finish at about -658.8 K this year. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
-693.5 K
Current Value
-658.8 K
Quarterly Volatility
1.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Brainstorm Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brainstorm Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 226.4 K, Interest Expense of 65.8 K or Selling General Administrative of 4.4 M, as well as many indicators such as Price To Sales Ratio of 17.14, Dividend Yield of 0.0 or Days Sales Outstanding of 21.66. Brainstorm financial statements analysis is a perfect complement when working with Brainstorm Cell Valuation or Volatility modules.
  
Build AI portfolio with Brainstorm Stock
Check out the analysis of Brainstorm Cell Correlation against competitors.
The Current Deferred Revenue trend for Brainstorm Cell Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Brainstorm Cell is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Brainstorm Cell's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Brainstorm Cell Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Brainstorm Cell's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brainstorm Cell's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Brainstorm Current Deferred Revenue Regression Statistics

Arithmetic Mean753,428
Coefficient Of Variation215.16
Mean Deviation1,541,294
Median(603,000)
Standard Deviation1,621,042
Sample Variance2.6T
Range3.3M
R-Value(0.74)
Mean Square Error1.3T
R-Squared0.54
Significance0.0008
Slope(236,126)
Total Sum of Squares42T

Brainstorm Current Deferred Revenue History

2026-658.8 K
2025-693.5 K
2018-603 K
20112.6 M
2010 6509.0

About Brainstorm Cell Financial Statements

Investors use fundamental indicators, such as Brainstorm Cell's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Brainstorm Cell's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-693.5 K-658.8 K

Currently Active Assets on Macroaxis

When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:
Check out the analysis of Brainstorm Cell Correlation against competitors.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is there potential for Biotechnology market expansion? Will Brainstorm introduce new products? Factors like these will boost the valuation of Brainstorm Cell. Projected growth potential of Brainstorm fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.33)
Return On Assets
(4.00)
Return On Equity
(11.22)
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Brainstorm Cell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Brainstorm Cell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Brainstorm Cell's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.